deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02345226

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects

Sponsor: Gilead Sciences

Conditions HIV-1 Infection
Interventions EFV/FTC/TDF EFV/FTC/TDF Placebo FTC/RPV/TAF FTC/RPV/TAF Placebo
Updated 14 times since 2017 Last updated: Dec 16, 2019 Started: Jan 26, 2015 Primary completion: Jun 29, 2016 Completion: Jan 2, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV-1 Infection and is currently completed. Gilead Sciences leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Apr 2019 — Feb 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Nov 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  4. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Alicante, Spain , Annandale, United States , Atlanta, United States , Aurora, United States , Austin, United States , Barcelona, Spain , Basel, Switzerland , Berkley, United States , Berlin, Germany and 74 more locations